- Coronary Stents Coronary Balloons Catheters Guide Wires Introducer Sheaths Accessories Peripheral Interventional Products
- Immunoassay Molecular Diagnostics Hematology Diagnostics POCT Lab Solution
- Structural Heart Diseases Products
- Vascular Access Blood Pressure Transducer Arterial Blood Sampler CVC Accessories IV Catheter Needle-free Connectors Insulin Injection Pain Relief
- Hemodialysis consumables Hemoperfusion Cartridge Dialysis machine
- ECG Patient Monitor Oximeter
- Cardiovasculars Oncology Anti-infectives Central Nervous System Others
- Endoscope Endoscopic Ultrasound System
- Trauma Implant Spinal Implant Artificial Joint Sports Medicine
- Pacemakers and Leads Equipments
- Metabolic Diseases Cardiovascular Diseases
- ELISA CLIA FIA
- Nucleic Acid Extraction Nucleic Acid Extraction ＆ PCR Kits Real-Time PCR
- Thrombelastography Analyzer Blood Grouping Platelet Aggregation
- POCT - FIA Colloidal Gold
- NeoECG Holter Monitor Portable ECG Monitor AI-ECG Pocket ECG
- Patient Monitor Vital Signs Monitor End-tidal Capnography
- Fingertip Oximeter Handheld Oximeter Wrist Oximeter Wearable Oximeter All-in-One Health Monitor POCT Solution
- OBS Locking Compression Plate Locking Plates Conventional Plates Mini Plates System Screws Patella Ring - Patented Product Metal Pins Cable System
- Internal Fixation System Laminoplasty Plate System Percutaneous Kyphoplasty Fusion Cage Cervical Fixation System
- Hip System Knee System
- Suture Anchor Suture Button
Clinical Trials
View onClinicalTrials.gov
Development Highlights:
1. Upstream RAS Targeting:
Designed to silence angiotensinogen (AGT) expression, reducing the precursor available for downstream angiotensin production and modulating the renin–angiotensin system (RAS) at its source.
2. RNAi-Based Antihypertensive Approach:
An investigational siRNA approach to blood pressure management that suppresses AGT synthesis, offering a distinct mechanism from therapies that inhibit downstream RAS enzymes or receptors.
3. Potential for Sustained Action:
Designed for sustained AGT suppression following subcutaneous administration, with the potential to support infrequent dosing for long-term hypertension management.
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
